REGULATORY FRAMEWORK GOVERNING GENOME-SCALE DNA SYNTHESIS OVERSIGHT IN JAPAN

1. INTRODUCTION

Genome-scale DNA synthesis involves the artificial production of extensive DNA sequences for scientific research, biotechnology, pharmaceutical development, and synthetic biology. Although it offers significant scientific benefits, it also creates biosecurity concerns because synthetic nucleic acids may potentially be misused.

Japan's regulatory approach combines biosafety legislation, infectious disease controls, research ethics, export controls, and institutional oversight. However, an important distinction exists between regulating genetically modified organisms and regulating the commercial ordering of synthetic DNA. Japan has not yet established a comprehensive statutory system specifically requiring sequence and customer screening by DNA synthesis providers.

2. PRINCIPAL LEGAL FRAMEWORK

A. Cartagena Act 2003

The Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms (Act No. 97 of 2003) is Japan's principal GMO regulatory legislation.

It regulates the use, handling, importation, and environmental release of living modified organisms.

Its principal requirements include:

Prior approval for applicable Type 1 use involving environmental release.

Containment measures for Type 2 use.

Risk assessment and regulatory documentation.

Compliance with applicable laboratory and industrial containment requirements.

Information disclosure and monitoring where legally required.

Importantly, the Act does not automatically regulate every artificially synthesized DNA molecule. Its application depends on whether the relevant material or activity falls within the statutory definition of a living modified organism.

B. Infectious Diseases Control Act

The Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases regulates specified pathogens and infectious agents.

It establishes controls over relevant pathogen possession, transfer, transportation, importation, and handling.

These provisions are important where synthetic DNA is associated with regulated biological agents. However, regulation of the agents themselves should not be confused with a general statutory screening obligation covering every synthetic DNA order.

C. Export Control Regulations

Japan's Foreign Exchange and Foreign Trade Act (FEFTA) provides the framework for controlling exports of specified goods and technologies.

Relevant biotechnology exports may require authorization depending on their classification and applicable control lists.

D. Research and Institutional Oversight

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) supervises relevant research activities through applicable genetic engineering regulations and institutional requirements.

Research institutions must assess applicable containment, safety, and ethical obligations before undertaking regulated activities.

3. SYNTHETIC DNA ORDER-SCREENING REQUIREMENTS

A significant regulatory development occurred during Japan's 2026 parliamentary discussions.

On 10 June 2026, government representatives acknowledged that Japan's existing legislation did not establish a specific mandatory screening system for synthetic nucleic acids themselves.

On 12 June 2026, government representatives further acknowledged that domestic contract synthesis providers were not subject to specific mandatory sequence-screening and customer-screening requirements.

The government indicated that it intended to examine industry practices and coordinate with relevant ministries and businesses.

Consequently, the following distinction is important:

Existing pathogen and GMO legislation remains applicable within its statutory scope.

General synthetic DNA order screening is not independently subject to a comprehensive mandatory statutory regime.

Customer verification and sequence screening may be adopted voluntarily through institutional or industry biosecurity policies.

A dedicated statutory framework remains an important regulatory development.

4. REGULATORY AUTHORITIES

The principal institutions include:

MEXT: Research-related genetic engineering oversight.

Ministry of Health, Labour and Welfare (MHLW): Infectious disease and pathogen-related controls.

Ministry of Economy, Trade and Industry (METI): Relevant industrial biotechnology and export-control matters.

Ministry of the Environment: Environmental protection and biodiversity regulation.

Cabinet Office: Coordination of national science, technology, and biosecurity policy.

5. IMPORTANT JUDICIAL DECISIONS

There are no established Japanese appellate judgments specifically determining liability for genome-scale DNA synthesis or failure to screen synthetic DNA orders. The following authorities are relevant principally by analogy.

1. Genetically Modified Rice Litigation (2005–2009)

Farmers challenged experimental genetically modified rice cultivation and sought an injunction and damages. The litigation was ultimately unsuccessful because the plaintiffs failed to establish the necessary basis for their claims.

Legal significance: Scientific risk allegations must be supported by sufficient evidence. Regulatory compliance does not automatically establish liability, but neither does it eliminate every possible civil claim.

Application: Relevant to disputes involving risks arising from synthetic biology research.

2. Osaka Airport Case (1981)

Supreme Court of Japan.

The Court examined issues concerning public nuisance, governmental responsibility, and the limits of judicial intervention.

Legal significance: Demonstrates the importance of examining public interests and legally recognized remedies when scientific or industrial activities create risks.

Application: Analogous to disputes concerning potentially harmful biotechnology facilities.

3. Minamata Disease Litigation

Japanese courts examined corporate responsibility for industrial pollution and resulting health damage.

Legal significance: Supports the importance of corporate responsibility and legally established liability for harmful industrial activities.

Application: Relevant by analogy where negligent biotechnology operations cause environmental or public-health injury.

4. Itai-itai Disease Litigation

The litigation concerned industrial pollution and responsibility for resulting human injury.

Legal significance: Illustrates the importance of causation, evidence, and compensation in environmental liability.

Application: Relevant to potential environmental consequences of biotechnology operations.

5. Japanese Administrative Law and Judicial Review Principles

Japanese administrative courts recognize judicial review of administrative action within the applicable statutory framework.

Legal significance: Regulatory decisions concerning biotechnology must remain within lawful administrative authority.

Application: Relevant to challenges involving licensing, regulatory enforcement, and government restrictions.

6. Japanese Environmental Litigation Principles

Japanese environmental litigation has developed principles concerning environmental protection, causation, and the evidentiary requirements for injunctions and compensation.

Legal significance: Scientific uncertainty does not automatically establish liability; the relevant statutory and civil-law requirements must be demonstrated.

Application: Relevant to disputes involving environmental consequences of synthetic biology.

These six authorities and categories are not direct precedents establishing synthetic DNA screening obligations. The first is the closest biotechnology-specific Japanese litigation example.

6. LIABILITY AND ENFORCEMENT

Potential legal consequences depend on the particular activity and applicable legislation.

Unauthorized use or release of regulated living modified organisms may attract Cartagena Act sanctions.

Unlawful handling of regulated pathogens may attract infectious disease legislation penalties.

Unauthorized controlled exports may result in FEFTA enforcement.

Negligent laboratory activities may create civil liability under applicable Japanese law.

Unauthorized disclosure of protected personal information may attract applicable data-protection consequences.

7. PRACTICAL COMPLIANCE REQUIREMENTS

Biotechnology institutions and synthesis providers should establish appropriate governance arrangements, including:

Legal classification of materials and research activities.

Institutional biosecurity policies.

Responsible customer and institutional verification.

Appropriate review of orders presenting legitimate biosecurity concerns.

Secure records and confidentiality controls.

Applicable pathogen and GMO regulatory compliance.

Export-control assessments.

Employee training and accountability.

Incident reporting arrangements.

Periodic independent compliance reviews.

8. CONCLUSION

Japan's genome-scale DNA synthesis oversight framework remains an evolving area of biotechnology governance. The Cartagena Act, Infectious Diseases Control Act, FEFTA, and institutional research requirements provide important controls over biological materials, regulated organisms, pathogens, and biotechnology activities.

However, these laws do not collectively establish a comprehensive mandatory screening regime for all synthetic DNA orders. Japan's June 2026 parliamentary discussions expressly recognized this regulatory gap.

The principal legislative challenge is to establish proportionate oversight that protects national biosecurity without unnecessarily restricting legitimate scientific research, pharmaceutical innovation, and biotechnology development. A future framework should clarify provider responsibilities, customer verification, institutional accountability, regulatory supervision, and appropriate legal remedies.